title: Cytochrome P450 polymorphisms and their relationship with premature ovarian failure in premenopausal women with breast cancer receiving doxorubicin and cyclophosphamide.
authors.forename: Alette M
authors.initials: AM
authors.lastname: Wessels
authors.forename: David A
authors.initials: DA
authors.lastname: Flockhart
authors.forename: Janet S
authors.initials: JS
authors.lastname: Carpenter
authors.forename: Milan
authors.initials: M
authors.lastname: Radovich
authors.forename: Lang
authors.initials: L
authors.lastname: Li
authors.forename: Kathy D
authors.initials: KD
authors.lastname: Miller
authors.forename: George W
authors.initials: GW
authors.lastname: Sledge
authors.forename: Anna M
authors.initials: AM
authors.lastname: Storniolo
authors.forename: Julie L
authors.initials: JL
authors.lastname: Otte
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Lemler
authors.forename: Bryan P
authors.initials: BP
authors.lastname: Schneider
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000568:Amenorrhea / Q000139:chemically induced* / Q000235:genetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005787:Gene Frequency; D006801:Humans; D008875:Middle Aged; D010865:Pilot Projects; D020641:Polymorphism, Single Nucleotide; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced* / Q000235:genetics; D055815:Young Adult
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide; D003577:Cytochrome P-450 Enzyme System